When it is not Type 1 or Type 2 Diabetes mellitus: A case of Slowly Evolving Immune-mediated Diabetes of Adult
DOI:
https://doi.org/10.60787/tnhj.v23i4.759Keywords:
C-peptide, diabetes mellitus, islet cell autoantibodies, latent autoimmune diabetes of adultAbstract
Background: Slowly Evolving Immune-mediated Diabetes of Adult (SEIDA) previously termed Latent Autoimmune Diabetes of Adult (LADA) is a heterogenous disorder characterized by the presence of serum islet autoantibodies at diagnosis with slow progression of islet failure. These patients often require insulin therapy within six months of diagnosis. Most of the presenting clinical symptoms can mimic either type 1 or type 2 diabetes mellitus.
Methods: We report a clinical case of a 37-year-old woman who was newly diagnosed with Type 2 diabetes mellitus.
Finding: She presented with history of polyuria, polydipsia, and weight loss of six months duration with a family history of type 2 diabetes mellitus in her father. She presented with worsening glycemic control despite her adherence to her medications. A clinical suspicion of SEIDA was made in view of her age and worsening glycemic control. This was confirmed with a positive result of serum Glutamic Acid Decarboxylase -65 (GAD-65) and low serum c-peptide levels.
Conclusion: This is to alert physicians that not all diabetes mellitus is type 1 or type 2 hence SEIDA should be suspected in any young adults presenting with features of uncontrolled diabetes mellitus in spite of optimal doses of oral hypoglycemic agents.
Downloads
References
World Health Organization. (2019). Classification of diabetes mellitus. World Health Organization. https://apps.who.int/iris/handle/10665/325182.
Rajkumar V, Levine SN. Latent Autoimmune Diabetes. [Updated 2022 Jun 21]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Jan 2023: https://www.ncbi.nlm.nih.gov/books/NBK557897/
Raffaella Buzzetti, Tiinamaija Tuomi, Didac Mauricio, Massimo Pietropaolo, Zhiguang Zhou, Paolo Pozzilli, Richard David Leslie; Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement from an International Expert Panel. Diabetes 1 October 2020; 69: 2037–2047.
Adeleye OO, Ogbera AO, Fasanmade O, Ogunleye OO, Dada AO, Ale AO, Abatan FM. Latent Autoimmune Diabetes Mellitus in Adults (LADA) and its characteristics in a subset of Nigerians initially managed for type 2 diabetes. Int Arch Med. 2012; 15:23-26.
Muazu SB, Okpe I, Anumah F. The prevalence and characteristics of latent autoimmune diabetes in adults’ subset among type two diabetes mellitus patients in Northern Nigeria. Ann Afr Med. 2016; 15:163-170.
Arinola Ipadeola, Jokotade O. Adeleye, Kehinde S. Akinlade, Latent autoimmune diabetes amongst adults with type 2 diabetes in a Nigerian tertiary hospital. Primary Care Diabetes. 2015;9: 231-236,
Nark RG, Brooks –Worrell BM, Palmer JP. Latent autoimmune diabetes in adult. J clin Endocrinol Metab 2009;94: 4635-4644
Pipi E, Marketou M, Tsirogianni A. Distinct clinical and laboratory characteristics of latent autoimmune diabetes in adult in relation to type 1 and type 2 diabetes mellitus. World J Diabetes 2014;5:505-510
Fourlanos S, Dotta F, Greenbaum CJ. Latent autoimmune diabetes in adult (LADA) should be less latent. Diabetologia 2005;48: 2206-2212
Tuomi T, Gnop LC, Zimmet PZ. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adult with a non-insulin-dependent onset of disease. Diabetes 1993;42: 359-362
Tiberti C, Giordano C, Locatelli M. Identification of tyrosine phosphatase 2 as a new sensitive marker for the detection of islet autoimmunity in type 2 diabetes patients. Diabetes 2008; 57: 1276-1283
Johansen OE, Bocm BO, Grill V. C peptide levels in latent autoimmune diabetes of adult treated with linagliptin versus glimepiride exploratory results from a 2 year double blind randomized control study. Diabetes care 2014; 37: E11-E12.
Rajkumar V, Levine SN. Latent Autoimmune Diabetes. [Updated 2022 Jun 21]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557897/
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Journal and Publisher
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The Journal is owned, published and copyrighted by the Nigerian Medical Association, River state Branch. The copyright of papers published are vested in the journal and the publisher. In line with our open access policy and the Creative Commons Attribution License policy authors are allowed to share their work with an acknowledgement of the work's authorship and initial publication in this journal.
This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author.
The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations. While the advice and information in this journal are believed to be true and accurate on the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.
TNHJ also supports open access archiving of articles published in the journal after three months of publication. Authors are permitted and encouraged to post their work online (e.g, in institutional repositories or on their website) within the stated period, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). All requests for permission for open access archiving outside this period should be sent to the editor via email to editor@tnhjph.com.
